Balloon-based drug coating delivery to the artery wall is dictated by coating micro-morphology and angioplasty pressure gradients
Source abstract
Abstract
Paclitaxel coated balloon catheters (PCB) were developed as a polymer-free non-implantable alternative to drug eluting stents, delivering similar drug payloads in a matter of minutes. While PCB have shown efficacy in treating peripheral arterial disease in certain patient groups, restenosis rates remain high and there is no class effect. To help further optimize these devices, we developed a scanning electron microscopy (SEM) imaging technique and computational modeling approach that provide insights into the coating micromorphology dependence of in vivo drug transfer and retention. PCBs coated with amorphous/flaky or microneedle coatings were inflated for 60 sec in porcine femoral arteries. Animals were euthanized at 0.5, 24 and 72 h and treated arteries processed for SEM to image endoluminal coating distribution followed by paclitaxel quantification by mass spectrometry (MS). Endoluminal surfaces exhibited sparse coating patches at 0.5 h, predominantly protruding (13.71 vs 0.59%, P < 0.001), with similar micro-morphologies to nominal PCB surfaces. Microneedle coating covered a 1.5-fold endoluminal area (16.1 vs 10.7%, P = 0.0035) owing to higher proximal and distal delivery, and achieved 1.5-fold tissue concentrations by MS (1933 vs 1298 μg/g, P = 0.1745) compared to amorphous/flaky coating. Acute longitudinal coating distribution tracked computationally predicted microindentation pressure gradients (r = 0.9, P < 0.001), with superior transfer of the microneedle coatings attributed to their amplification of angioplasty contact pressures. By 24 h, paclitaxel concentration and coated tissue areas both declined by >93% even as nonprotruding coating levels were stable between 0.5 and 72 h, and 2.7-fold higher for microneedle vs flaky coating (0.64 vs 0.24%, P = 0.0195). Tissue retained paclitaxel concentrations at 24-72 h trended 1.7-fold higher post treatment with microneedle coating compared to the amorphous/flaky coating (69.9 vs 39.9 μg/g, P = 0.066). Thus, balloon based drug delivery is critically dependent on coating micromorphologies, with superior performance exhibited by micromorphologies that amplify angioplasty pressures.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Coronary Interventions and Diagnostics · Electrospun Nanofibers in Biomedical Applications · Tribology and Lubrication Engineering
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (41)
Show source-provided references
1. Long-term clinical effectiveness of a drug-coated balloon for the treatment of femoropopliteal lesions10.1161/CIRCINTERVENTIONS.118.007702 ↗
2. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months10.1016/S0735-1097(00)01020-2 ↗
3. Arterial paclitaxel distribution and deposition10.1161/01.RES.86.8.879 ↗
4. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel10.1073/pnas.0400918101 ↗
5. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery10.1161/01.CIR.96.2.636 ↗
6. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis10.1161/01.CIR.0000138929.71660.E0 ↗
7. How does a drug-coated balloon work? Overview about coating technologies and their impact
8. Drug-coated balloon treatment for lower extremity vascular disease intervention: an international positioning document10.1093/eurheartj/ehv204 ↗
9. Dose response to paclitaxel-coated balloon catheters in the porcine coronary overstretch and stent implantation model10.1097/RLI.0b013e31820577df ↗
10. Impact of paclitaxel dose on tissue pharmacokinetics and vascular healing: a comparative drug-coated balloon study in the familial hypercholesterolemic swine model of superficial femoral in-stent restenosis10.1016/j.jcin.2015.03.020 ↗
11. Mechanisms of tissue uptake and retention of paclitaxel-coated balloons: impact on neointimal proliferation and healing10.1136/openhrt-2014-000117 ↗
12. Sustainable antirestenosis effect with a low-dose drug-coated balloon: the illumenate european randomized clinical trial 2-year results10.1016/j.jcin.2018.08.034 ↗
13. The era of drug-coated balloons: are all created equal?10.1016/j.jcin.2018.10.001 ↗
14. Tissue concentration of heparin, not administered dose, correlates with the biological response of injured arteries in vivo10.1073/pnas.96.20.11111 ↗
15. Physiological transport forces govern drug distribution for stent-based delivery10.1161/hc3101.092214 ↗
16. Defining drug and target protein distributions after stent-based drug release: durable versus deployable coatings10.1016/j.jconrel.2018.02.007 ↗
17. Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease10.1007/s00270-014-0904-3 ↗
18. Taking paclitaxel coated balloons to a higher level: predicting coating dissolution kinetics, tissue retention and dosing dynamics10.1016/j.jconrel.2019.08.019 ↗
19. Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel?10.1161/CIRCINTERVENTIONS.111.967794 ↗
20. Mechanisms of tissue uptake and retention in zotarolimus-coated balloon therapy10.1161/CIRCULATIONAHA.113.002051 ↗
21. Biological effect on drug distribution and vascular healing via paclitaxel-coated balloon technology in drug eluting stent restenosis swine model
22. Drug distribution and basic pharmacology of paclitaxel/resveratrol-coated balloon catheters10.1007/s00270-018-2018-9 ↗
23. Fiji: an open-source platform for biological-image analysis10.1038/nmeth.2019 ↗
24. Assessment of vascular injury during stent placement using contact mechanics
25. Intrinsic coating morphology modulates acute drug transfer in drug-coated balloon therapy10.1038/s41598-019-43095-9 ↗
26. General relations of indentations on solids with surface tension
27. Hertz theory: contact of cylindrical surfaces
28. Stress--strain analysis of a longitudinal heterogeneous arterial wall
29. Rate of drug coating dissolution determines in-tissue drug retention and durability of biological efficacy10.1155/2019/9560592 ↗
30. Nanomechanical properties of calcification, fibrous tissue, and hematoma from atherosclerotic plaques10.1002/jbm.a.32321 ↗
31. Regional material property alterations in porcine femoral arteries with atheroma development10.1016/j.jbiomech.2004.10.018 ↗
32. Pharmacokinetic study of paclitaxel concentration after drug-eluting balloon angioplasty in the iliac artery of healthy and atherosclerotic rabbit models10.1016/j.jvir.2015.05.022 ↗
33. Paclitaxel-coated balloons: Investigation of drug transfer in healthy and atherosclerotic arteries - first experimental results in rabbits at low inflation pressure10.1007/s10557-016-6658-1 ↗
34. The role of van der waals forces in adhesion of micromachined surfaces10.1038/nmat1431 ↗
35. More evidence and more questions about paclitaxel-coated balloons in the femoropopliteal segment10.1016/j.jcin.2018.02.039 ↗
36. Mortality and paclitaxel-coated devices: an individual patient data meta-analysis10.1161/CIRCULATIONAHA.119.044697 ↗
37. Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon10.1016/j.jacc.2019.01.013 ↗
38. Association of survival with femoropopliteal artery revascularization with drug-coated devices10.1001/jamacardio.2019.0325 ↗
39. Survival after coronary revascularization with paclitaxel-coated balloons10.1016/j.jacc.2019.11.065 ↗
40. Comparison of particulate embolization after femoral artery treatment with in.Pact admiral versus lutonix 035 paclitaxel-coated balloons in healthy swine10.1016/j.jvir.2016.06.036 ↗
41. Linear micro-patterned drug eluting balloon (lmdeb) for enhanced endovascular drug delivery10.1038/s41598-018-21649-7 ↗